A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity

R. D. Petty (Lead / Corresponding author), M. C. Nicolson, S. Skaria, T. S. Sinclair, L. M. Samuel, M. Koruth, Aberdeen Pancreatic Cancer Focus Group

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    BACKGROUND: The effective treatment of unresectable pancreatic carcinoma represents a formidable challenge. There is a need to develop systemic therapies which combine efficacy with acceptable toxicity. The current 'gold standard' gemcitabine gives an objective response rate of the order of 20% and median survival up to 6 months. Here we have evaluated the efficacy and toxicity of mitomycin C, cisplatin and protracted infusional 5-fluorouracil (MCF).

    PATIENTS AND METHODS: Forty-five patients with locally advanced (13 patients) or metastatic (32 patients) pancreatic carcinoma were treated with mitomycin C 7 mg/m2 6 weekly, cisplatin 60 mg/m2 3 weekly and protracted venous infusion 5-FU 300 mg/m2/day. Patients were evaluated for response after three cycles and received six cycles in total in the absence of progressive disease or poor tolerance. Median age was 62 (45-75) years; 41 patients were World Health Organization performance status 0-1.

    RESULTS: Treatment was well tolerated with 36 (84%) patients completing three or more cycles. Grade 3 or 4 toxicities were uncommon: anaemia in three patients (7%), mucositis in two (5%), nausea and vomiting in three (7%) and diarrhoea in one (1%). An objective response was seen in 21 (46%) patients. There was one complete response. The median survival overall was 7.1 months and 10.5 months in responders. The median duration of response was 4.3 months. One-year survival was 29%, 2-year survival was 18%.

    CONCLUSIONS: MCF combines efficacy with low toxicity in the treatment of advanced pancreatic carcinoma. The efficacy is at least comparable and may be superior to single-agent gemcitabine and MCF may therefore provide a cost-effective alternative.

    Original languageEnglish
    Pages (from-to)1100-1105
    Number of pages6
    JournalAnnals of Oncology
    Volume14
    Issue number7
    DOIs
    Publication statusPublished - Jul 2003

    Keywords

    • Aged
    • Antineoplastic Combined Chemotherapy Protocols
    • Carcinoma
    • Cisplatin
    • Female
    • Fluorouracil
    • Humans
    • Infusions, Intravenous
    • Male
    • Middle Aged
    • Mitomycins
    • Pancreatic Neoplasms
    • Survival Analysis
    • Treatment Outcome

    Fingerprint Dive into the research topics of 'A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity'. Together they form a unique fingerprint.

  • Cite this

    Petty, R. D., Nicolson, M. C., Skaria, S., Sinclair, T. S., Samuel, L. M., Koruth, M., & Aberdeen Pancreatic Cancer Focus Group (2003). A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity. Annals of Oncology, 14(7), 1100-1105. https://doi.org/10.1093/annonc/mdg278